COGT · Cogent Biosciences, Inc.
$37.93
+0.62 (+1.66%)
At close · Aug 14
Market Cap
$6.58B
Shares
173.52M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Andrew Robbins | Chief Executive Officer | $27,762,684 |
| Jessica Sachs | Chief Medical Officer | $9,178,177 |
| John Robinson | Chief Scientific Officer | $9,150,297 |
| Cole Pinnow | Chief Commercial Officer | $8,839,548 |
| John Green | Chief Financial Officer | $8,546,329 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Andrew Robbins | Chief Executive Officer | $4,917,890 |
| Cole Pinnow | Chief Commercial Officer | $3,969,744 |
| Jessica Sachs | Chief Medical Officer | $1,832,714 |
| John Robinson | Chief Scientific Officer | $1,807,431 |
| John Green | Chief Financial Officer | $1,747,767 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Andrew Robbins | Chief Executive Officer | $7,898,772 |
| Jessica Sachs | Chief Medical Officer | $2,999,941 |
| John Robinson | Chief Scientific Officer | $2,975,911 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Andrew Robbins | Chief Executive Officer | $4,391,176 |
| Jessica Sachs | Chief Medical Officer | $1,907,927 |
| John Robinson | Chief Scientific Officer | $1,869,151 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Jessica Sachs | Chief Medical Officer | $3,809,193 |
| John Robinson | Chief Scientific Officer | $3,473,113 |
| Andrew Robbins | Chief Executive Officer | $2,862,878 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Andrew Robbins | Chief Executive Officer | $17,859,744 |
| John Green | Chief Financial Officer | $2,139,245 |
| Charles Wilson | Former Chief Executive Officer | $1,796,751 |
| Jessica Sachs | Chief Medical Officer | $1,189,457 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Charles Wilson | Former Chief Executive Officer | $1,717,416 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Todd Shegog | Director | Appointed | 2023-06-07 |
| Arlene M. Morris | Director | Appointed | 2023-06-07 |
| Chris Cain | Director | Appointed | 2023-06-07 |
Key facts
CIK
1622229
CUSIP
19240Q201
13F (30d)
312 filings
308 filers
Visit website
Investor relations